Coats disease in India: clinical presentation and outcome in 675 patients (690 Eyes)

Int Ophthalmol. 2023 Feb;43(2):531-540. doi: 10.1007/s10792-022-02451-x. Epub 2022 Aug 20.

Abstract

Purpose: To study the clinical profile, treatment, and visual outcome of patients with Coats disease in India.

Methods: This was a cross-sectional, observational hospital-based study of patients diagnosed with Coats disease during a 10-year period using an electronic medical record system.

Results: We identified 675 patients with Coats disease with a prevalence rate of 0.025%. The mean age of the patients was 16.8 years (median, 12 years). Majority were males (75%) with unilateral presentation (98%) in first decade of life (n = 309, 46%). The most common presentation was foveal exudation (stage 2B, n = 161, 23.3%), followed by exudative retinal detachment-extrafoveal (stage 3A1, n = 143, 20.7%), and extrafoveal exudation (stage 2A, n = 136, 19.7%). Treatment modalities included observation (48 eyes, 17%), laser photocoagulation ± intravitreal bevacizumab/triamcinolone acetonide (n = 82, 29%), cryotherapy ± intravitreal bevacizumab/triamcinolone acetonide (n = 64, 23%), and surgical intervention (n = 86, 31%). Despite appropriate treatment, at mean follow-up of 16 months, there was no significant difference between presenting and final visual acuity (48% vs. 48%, p > 0.05). Using multivariate regression analysis, factors associated with poor visual outcome were younger age (< 0.001; - 0.02 to - 0.1), unilateral disease (0.04; - 0.68 to - 0.01), cataract (0.004; 0.13 to 0.69), retinal detachment (< 0.001; 0.49 to 0.82), and glaucoma (< 0.001; 0.34 to 0.94).

Conclusion: The most common clinical presentation of Coats disease in India is foveal exudation in first and second decade. At initial presentation, about half of the affected eyes had blindness and one-third underwent surgical intervention.

Keywords: Big data; Clinical presentation; Coats disease; Electronic medical records.

Publication types

  • Observational Study

MeSH terms

  • Adolescent
  • Bevacizumab / therapeutic use
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Laser Coagulation
  • Male
  • Retinal Detachment* / diagnosis
  • Retinal Detachment* / epidemiology
  • Retinal Detachment* / therapy
  • Retinal Telangiectasis* / diagnosis
  • Retinal Telangiectasis* / epidemiology
  • Retinal Telangiectasis* / therapy
  • Retrospective Studies
  • Triamcinolone Acetonide

Substances

  • Bevacizumab
  • Triamcinolone Acetonide